Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Survival of Patients with Prostate Cancer in Yazd, Iran

  • Published : 2014.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Prostate cancer is the second leading cause of cancer death in men worldwide. Several factors such as availability of screening tests, and dietary, other lifestyle, environmental and genetic influences contribute to worldwide disparities in prostate cancer incidence and mortality rates. Our aims were to investigate patient characteristics at the time of diagnosis, common treatment strategies employed and survival in an Iranian male population with prostate cancer. Materials and Methods: Archives of Pathology Departments of five referral centers affiliated with the School of Medicine of Shahid Sadoughi University in Yazd province were reviewed. Paraffin-embedded blocks were reviewed by two independent pathologists to confirm the diagnosis. The latest modification of the Gleason Scoring System was adopted to determine pathological grading. Following pathological evaluation, patients were contacted via telephone to acquire information regarding their current status. Results: Pathology blocks were available for 113 patients. However, upon phone contacts, we were unable to determine the survival status in 23 patients (response rate=83%). Therefore, 90 patients were enrolled in the final analysis. The median follow-up time was 6.0 years (ranging from 0.3 to 8.8 years). There were 30 death attributed to prostate cancer in the study group. Kaplan-Meier analysis revealed that patient age at the time of diagnosis was a significant predictor of survival. Another significant predictor of poorer survival was higher tumor grade. Conclusions: Our observations indicate that age and pathological grade can negatively affect survival of individuals with prostate cancer in Iran.

Keywords

References

  1. Andren O, Fall K, Franzen L, et al (2006). How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol, 175, 1337-40. https://doi.org/10.1016/S0022-5347(05)00734-2
  2. Bostwick DG, Burke HB, Djakiew D, et al (2004). Human prostate cancer risk factors. Cancer, 101, 2371-490. https://doi.org/10.1002/cncr.20408
  3. Bouchardy C, Mirra AP, Khlat M, et al (1991). Ethnicity and cancer risk in Sao Paulo, Brazil. Cancer Epidemiol Biomarkers Prev, 1, 21-7.
  4. Chan TY, Partin AW, Walsh PC, Epstein JI (2000). Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urol, 56, 823-7. https://doi.org/10.1016/S0090-4295(00)00753-6
  5. Crawford ED (2003). Epidemiology of prostate cancer. Urology, 62, 3-12.
  6. Crawford ED (2009). Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology, 73, 4-10. https://doi.org/10.1016/j.urology.2008.07.066
  7. Dunn JE (1975). Cancer epidemiology in populations of the United States--with emphasis on Hawaii and California--and Japan. Cancer Res, 35, 3240-5.
  8. Epstein JI (2010). An update of the Gleason grading system. J Urol, 183, 433-40. https://doi.org/10.1016/j.juro.2009.10.046
  9. Holmberg L, Robinson D, Sandin F, et al (2012). A comparison of prostate cancer survival in England, Norway and Sweden: A population-based study. Cancer Epidemiol, 36, 7-12. https://doi.org/10.1016/j.canep.2011.08.001
  10. Hsing AW, Tsao L, Devesa SS (2000). International trends and patterns of prostate cancer incidence and mortality. Int J Cancer, 85, 60-7. https://doi.org/10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B
  11. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  12. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  13. Jemal A, Thomas A, Murray T, Thun M (2002). Cancer statistics, 2002. CA Cancer J Clin, 52, 23-47. https://doi.org/10.3322/canjclin.52.1.23
  14. Kramer BS, Hagerty KL, Justman S, et al (2009). Use of 5-alphareductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol, 27, 1502-16. https://doi.org/10.1200/JCO.2008.16.9599
  15. Makarov DV, Sanderson H, Partin AW, Epstein JI (2002). Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4+3 and 3+4 independent of the number of involved cores? J Urol, 167, 2440-2. https://doi.org/10.1016/S0022-5347(05)65000-8
  16. Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, Parkin M (2009). Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iran Med, 12, 15-23.
  17. Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
  18. Platz EA, Rimm EB, Willett WC, et al (2000). Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst, 92, 2009-17. https://doi.org/10.1093/jnci/92.24.2009
  19. Quinn M, Babb P (2002). Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int, 90, 162-73. https://doi.org/10.1046/j.1464-410X.2002.2822.x
  20. Rasiah KK, Stricker PD, Haynes AM, et al (2003). Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer, 98, 2560-5. https://doi.org/10.1002/cncr.11850
  21. Sadjadi A, Nooraie M, Ghorbani A, et al (2007). The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med, 10, 481-5.
  22. Shibata A, Whittemore AS (1997). Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate, 32, 65-72. https://doi.org/10.1002/(SICI)1097-0045(19970615)32:1<65::AID-PROS9>3.0.CO;2-B
  23. Siegel R, DeSantis C, Virgo K, et al (2012a). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41. https://doi.org/10.3322/caac.21149
  24. Siegel R, Naishadham D, Jemal A (2012b). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  25. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  26. Stark JR, Perner S, Stampfer MJ, et al (2009). Gleason score and lethal prostate cancer: does 3+4=4+3? J Clin Oncol, 27, 3459-64. https://doi.org/10.1200/JCO.2008.20.4669
  27. Theoret MR, Ning YM, Zhang JJ, et al (2011). The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med, 365, 97-9. https://doi.org/10.1056/NEJMp1106783
  28. Thompson IM, Jr., Goodman PJ, Tangen CM, et al (2013). Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med, 369, 603-10. https://doi.org/10.1056/NEJMoa1215932
  29. Watanabe M, Nakayama T, Shiraishi T, et al (2000). Comparative studies of prostate cancer in Japan versus the United States. A review. Urol Oncol, 5, 274-83. https://doi.org/10.1016/S1078-1439(00)00092-2
  30. Zlotta AR, Egawa S, Pushkar D, et al (2013). Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst, 105, 1050-8. https://doi.org/10.1093/jnci/djt151

Cited by

  1. Demographic Survey of Four Thousand Patients with 10 Common Cancers in North Eastern Iran over the Past Three Decades vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10193
  2. Application of a Network Scale-up Method to Estimate the Size of Population of Breast, Ovarian/Cervical, Prostate and Bladder Cancers vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3273